公开(公告)号：US20200085802A1

公开(公告)日：2020-03-19

申请号：US16495555

申请日：2018-03-20

Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Hyun Goo WOO ,  Sarah YOON ,  Eun-Ju LEE

IPC: A61K31/44 ,  C12Q1/6886 ,  G01N33/574 ,  A61K39/395 ,  A61K45/06

Abstract: The present invention relates to a method for predicting susceptibility to sorafenib treatment by using an SULF2 gene, and a composition for treatment of sorafenib-resistant cancer using the SULF2 expression inhibition. The method for predicting susceptibility to sorafenib treatment by using the SULF2 gene according to the present invention can enable achievement of an optimal therapeutic effect by administering a drug suitable for cancer patients, and the composition for treatment of sorafenib-resistant cancer using the SULF2 inhibition has a very excellent anticancer treatment effect.

公开(公告)号：US20240059741A1

公开(公告)日：2024-02-22

申请号：US18269708

申请日：2021-12-24

Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Hyun Goo WOO ,  Masaud SHAH ,  Sung Ung MOON

IPC: C07K14/00 ,  A61P31/14

CPC classification number: C07K14/001 ,  A61P31/14 ,  A61K38/00

Abstract: The present invention relates to a composition for prevention or treatment of SARS-CoV-2 infection. CSNP1, CSNP2, CSNP3, and CSNP4 bind to receptor the binding domain (RBD) of the spike protein of SARS-CoV-2 to inhibit the interaction of the spike protein of SARS-CoV-2 with ACE2, thereby interfering with the mechanism that SARS-CoV-2 enters cells or evades immunity. Thus, a composition comprising CSNP1, CSNP2, CSNP3, or CSNP4 as an active ingredient is provided as a pharmaceutical agent for prevention or treatment of SARS-CoV-2 infection (COVID19).